

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/58473 A1

(51) International Patent Classification⁷: **A61K 38/17, A61P 9/10**

(74) Agents: NAGY, Michael, R.; American Home Products Corporation, Patent Law Department - 2B, One Campus Drive, Parsippany, NJ 07054 et al. (US).

(21) International Application Number: PCT/US01/04048

(22) International Filing Date: 8 February 2001 (08.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/501,862 10 February 2000 (10.02.2000) US

(71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).

(72) Inventors: FRIEDRICH, Gregory, Scott; 901 Roelofs Road, Yardley, PA 19067 (US). SWILLO, Roberto, Edward; 411 Gordon Road, Ambler, PA 19002 (US). JOW, Brian, Hong-N; 42 Navesink Drive, Pennington, NJ 08534 (US). BRIDAL, Terry, Roy; 11-02 Aspen Way, Doylestown, PA 18901 (US). NUMANN, Randal, Edward; 10456 Harvestview Way, San Diego, CA 92128 (US). WARNER, Linda, Marie; 1130 Kolbe Lane, West Chester, PA 19382 (US). KILLAR, Loran, Marie; 2061 Farmview Drive, Newtown, PA 18940 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/58473 A1

(54) Title: METHOD OF TREATING OR INHIBITING CELLULAR INJURY OR CELL DEATH

(57) Abstract: This invention provides a method of treating or inhibiting cellular injury or cell death following an ischemic event, treating or inhibiting reperfusion injury, and reducing mortality following a myocardial infarction by providing therapy with a TNF α antagonist.

METHOD OF TREATING OR INHIBITING
CELLULAR INJURY OR CELL DEATH

5

This invention relates to treating or inhibiting cellular injury or cell death following an ischemic event, treating or inhibiting reperfusion injury, and reducing mortality following a myocardial infarction by providing therapy with a TNF α antagonist.

10

The reduction or cessation of blood flow to a vascular bed accounts for a variety of clinical events that require immediate intervention and restitution of adequate perfusion to the jeopardized organ or tissue. Different tissues can withstand differing degrees of ischemic injury. However, all tissues will progress to irreversible injury and cellular necrosis if not reperfused. Impaired perfusion of cardiac tissue (ischemia) results in a loss of the heart's ability to function properly as the tissue becomes oxygen and energy deprived. Permanent injury is directly related to the duration of the oxygen deficit the myocardium experiences. Reperfusion of ischemic tissue simply refers to the restoration of flow to that tissue or organ system. The 15 necessity of reperfusion, achieved by mechanical or pharmacological means has been accepted by the medical community, especially in the clinical setting of a myocardial infarction. Data suggests that "reperfusion injury" compromises the degree of tissue 20 salvage when blood flow returns to the tissue.

Therapeutic interventions such as coronary angioplasty and thrombolytic 25 therapy are directed toward the treatment of acute myocardial ischemia. It is well recognized that mortality among patients who are experiencing a myocardial infarction is dependent upon the extent of left ventricular dysfunction, which, in turn is directly related to the amount of myocardium that becomes infarcted and thus nonfunctional. There is general agreement that myocardial tissue subjected to an 30 ischemic interval is dependent upon the restoration of blood flow within a defined period for cellular viability and function to be restored.

- 2 -

Compromised tissue following ischemia can only be recovered by reperfusing it. Though the act of reperfusion can extend injury further. As investigators began to recognize this, studies were directed to explore the mechanisms responsible, as well as to develop potential therapies to suppress cellular damage associated with 5 reperfusion injury. A number of cellular mechanisms are believed to be responsible for ischemia-induced reperfusion injury.

TNF α is a cytokine secreted by macrophages and monocytes which causes a wide variety of effects on a number of cell types. TNF proteins initiate their 10 biological effect on cells by binding to specific TNF receptor (TNFR) proteins expressed on the plasma membrane of a TNF responsive cell. The effects caused by TNF α include inhibitory or cytotoxic effects on tumor cell lines, stimulation of the proliferation of fibroblasts and the phagocytic/cytotoxic activity of myeloid cells. induction of adhesion molecules in endothelial cells, inhibition of the synthesis of 15 specific enzymes in adipocytes, and induction of the expression of histocompatibility antigens. [see, US Patent 5,610,279]. TNF α also causes pro-inflammatory actions which result in tissue injury, such as degradation of cartilage and bone [Saklatvala. Nature 322: 547 (1986); Bertolini, Nature 319: 516 (1986)]. TNF α is also associated with infections, immune disorders, neoplastic pathologies, autoimmune pathologies. 20 and graft vs. host disease. TNF α is also implicated in causing a wasting syndrome known as cachexia associated with cancer, which includes progressive weight loss. anorexia, and persistent erosion of lean body mass in response to malignant growth. [see WO 98/51344].

TNF α is also believed to contribute to the induction of ventricular 25 dysfunction, pulmonary edema, and cardiomyopathy. [Torre-Amione G, J Am Coll Cardiol 27:1201-1206 (1996)] There is a growing body of evidence suggesting that components of the inflammatory cascade triggered by the binding of TNF to TNF receptor I and II (TNFR, p55, p75) are directly responsible for the acute deleterious effects observed in the myocardium [Oral, H., J Biol Chem. 272(8): 4836-4842 30 (1997); Kapadia, S., Am J. Physiol. 268: H517-H525 (1995)].

Inflammatory cytokines, including TNF, have been shown to be released by the myocytes immediately after the onset of ischemia [Meldrum, D.R., J Mol Cell

- 3 -

Cardiol. 30:1683-1689 (1998)] and are believed to be involved in the expression of adhesion molecules that are instrumental in neutrophil extravasation. The sphingomyelinase pathway can be initiated by the release of TNF, and is considered the predominant signaling pathway of the cytokine [Kim et al., J Biol Chem 266: 484-5 489 (1991); Dressler et al., Science 255: 1715-1718 (1992); Yang, et al. J Biol Chem 268: 20520-20523 (1993)]. This pathway has been demonstrated in cardiac myocytes. [Oral et al., J Biol Chem 272: 4836-4842 (1997)]. Sphingomyelinases can be activated by TNF to breakdown the membrane bound sphingomyelin to ceramide. In turn, endogenous ceramidases catabolize ceramide to sphingosine. Both ceramide 10 and sphingosine have been shown to possess second messenger properties. Sphingosine has been shown to depress cardiac function by decreasing calcium induced calcium release from the sarcoplasmic reticulum, as well as the ability to directly suppress L-type calcium current. Cain et al. [Crit Care Med. 27(7):1309-1318 (1999)] utilized stimulated human atrial trabeculae suspended in organ baths, and 15 recorded the developed force the tissue generated. Graded concentrations of TNF- α , IL-1 β or TNF- α + IL-1 β were added and function was assessed. In addition, the tissues were exposed N-oleoyl ethanolamine (NOE) before TNF- α or IL-1 β . TNF- α and IL-1 β each depressed human myocardial function in a concentration-dependent fashion. Inhibition of myocardial sphingosine by NOE abolished the myocardial 20 depressive effects of either TNF- α or IL-1 β . The investigators concluded that TNF- α and IL-1 β separately and synergistically depress human myocardial function. Sphingosine likely participates in the TNF-alpha and IL-1 beta signal leading to human myocardial functional depression.

Cell injury has also been demonstrated in other tissues. Adult human kidney 25 proximal tubular (HK-2) cells were cultured for 0-20 hr in the presence or absence of sphingosine and metabolites as well as C2, C8, or C16 ceramide. Sphingosine (> or = 10 microM), and selected ceramides (C2 and C8) each induced rapid, concentration-dependent cytotoxicity in the absence of DNA laddering or morphologic changes of apoptosis, suggesting a necrotic form of cell death. The investigators could reproduce 30 the results in human foreskin fibroblasts, suggesting broad-based relevance to the area of acute cell injury and repair [Iwata et al., PNAS 92(19):8970-8974 (1995)].

- 4 -

ENBREL (etanercept; p75TNFR:Fc) is a dimeric fusion protein consisting of the extracellular ligand-binding protein of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. Etanercept is a TNF α antagonist currently marketed for the treatment of rheumatoid arthritis, and 5 is undergoing clinical trials for treatment of chronic heart failure [Bozkurt B, JACC (Suppl) 184-185A (1999); Deswal A, Circulation (suppl) 96(8):I-323 (1997)].

WO 98/51344 discloses the use of a TNF α antagonist in combination with a VEGF antagonist for the treatment or prevention of TNF-mediated diseases including 10 rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.

DESCRIPTION OF THE INVENTION

This invention provides a method of treating or inhibiting cellular injury or 15 cell death following an ischemic event which comprises providing an effective amount of a TNF α antagonist. More particularly, this invention provides a method of treating or inhibiting cellular injury or cell death resulting from myocardial infarction, myocardial ischemia, retinal ischemia, central retinal occlusion, peripheral arterial occlusion (i.e., an embolism), transient ischemic attacks (i.e., cerebral ischemic 20 attacks), ischemic stroke, ischemic arterial obstruction, reperfusion injury resulting from frostbite, arterial thrombosis and occlusion, and crush injury by providing an effective amount of a TNF α antagonist. This invention also provides a method of reducing mortality following myocardial infarction by providing an effective amount of a TNF α antagonist. This invention additionally provides a method of inhibiting 25 cardiac damage following a cardiac ischemic event by providing an effective amount of a TNF α antagonist. This invention further provides a method of treating or inhibiting reperfusion injury by providing an effective amount of a TNF α antagonist.

As used in accordance with this invention, the term providing an effective 30 amount of a TNF α antagonist means either directly administering such antagonist, or administering a prodrug, derivative, or analog which will form an effective amount of the antagonist within the body.

The term TNF α antagonist has been well defined in WO 98/51344, and is defined as decreases, blocks, inhibits, abrogates or interferes with TNF α activity in vivo. For example, a suitable TNF α antagonist can bind TNF α and includes anti-TNF α antibodies, antigen-binding fragments thereof, and receptor molecules and derivatives which bind specifically to TNF α . A suitable TNF α antagonist can also prevent or inhibit TNF α synthesis and/or TNF α release and includes compounds such as thalidomide, tenidap, and phosphodiesterase inhibitors, such as, but not limited to, pentoxifylline and rolipram. A suitable TNF α antagonist that can prevent or inhibit TNF α synthesis and/or TNF α release also includes A2b adenosine receptor enhancers and A2b adenosine receptor agonists (e.g., 51-(N-cyclopropyl)-carboxamidoadenosine, 51-N-ethylcarboxamidoadenosine, cyclohexyladenosine and R-N6-phenyl-2-propyladenosine) See, for example, Jacobson, GB 2 289 218A. A suitable TNF α antagonist can also prevent or inhibit TNF α receptor signalling and includes mitogen activated protein (MAP) kinase inhibitors. Other suitable TNF α antagonists include agents which decrease, block, inhibit, abrogate or interfere with membrane TNF α cleavage, such as, but not limited to, metalloproteinase inhibitors; agents which decrease, block, inhibit, abrogate or interfere with TNF α activity, such as, but not limited to, angiotensin converting enzyme (ACE) inhibitors, such as captopril, enalapril and lisinopril; and agents which decrease, block, inhibit, abrogate or interfere with TNF α production and/or synthesis, such as, but not limited to, MAP kinase inhibitors.

It is preferred that the TNF α antagonist is a TNF receptor molecule that binds TNF α . It is more preferred that the TNF receptor molecule is a TNF receptor fragment/immunoglobulin fusion protein. It is still more preferred that the fusion protein comprises a fragment of TNFR and a portion or the entire constant region of a human immunoglobulin heavy chain.

A particularly preferred TNF α antagonist is etanercept (p75TNFR:Fc), which is a dimeric fusion protein consisting of the extracellular ligand-binding protein of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. Etanercept is commercially available as ENBREL, and is currently approved for use in treating rheumatoid arthritis. Etanercept can be

- 6 -

prepared according to the procedures described in US Patents 5,605,690, 5,478,925. EP 464533, and EP670730, which are hereby incorporated by reference.

Another preferred TNF α antagonist is designated as p55TNFR:Fc, which is a
5 dimeric fusion protein consisting of the extracellular ligand-binding protein of the human 55 kilodalton (p55) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The production of p55TNFR:Fc is disclosed in US Patent 5,610,279, which is incorporated by reference.

10 The ability of TNF α antagonists to treat or inhibit cellular injury or cell death following an ischemic event and to treat or inhibit reperfusion injury was evaluated in two in vivo standard pharmacological test procedures. The first test procedure evaluated the effects of TNF and sphingosine on cardiac function, and the second test procedure evaluated the survival after a 30 minute occlusion of the main coronary
15 artery followed by reperfusion. Etanercept was evaluated as a representative TNF α antagonist in the second test procedure which emulates an acute myocardial infarction. An in vitro standard pharmacological test procedure was also performed to evaluate the cardiodepressant effect of sphingosine on myocytes. The procedures used and results obtained are described below.

20

Procedures

Surgical preparation. Male Sprague-Dawley rats weighing 505 \pm 5g were anesthetized with sodium pentobarbital (50 mg/kg I.P.). An endotracheal tube was secured in place and connected to a small-animal respirator (Harvard Apparatus, 25 Model 683, South Natick, MA) set on 100 breaths/min, with a tidal volume of 2-3 mL/breath. Body temperature was maintained using a heating pad with circulating warm water (K-model 100, Baxter Laboratories). A left thoracotomy was performed. the heart exposed and the pericardium removed. Left ventricular pressure was measured using a saline-filled polyethylene catheter attached to an angiocatheter (20 30 Gauge) inserted through the apex of the heart and connected to a P23 ID Statham/Gould pressure transducer. Arterial pressure was monitored via a saline-filled polyethylene catheter (PE 50) introduced into the left carotid artery. The right

- 7 -

jugular vein was also cannulated with a polyethylene catheter (PE 50) for IV drug infusions and volume repletion (0.9% NaCl). Subcutaneous needles were positioned in the limbs for ECG recordings. All data outputs were recorded on a Gould Model 6600 (Valley View, OH) series recorder with a Po-Ne-Mah data acquisition system (Valley View, OH) and displayed on a physiology platform CRS800W/ CRS400W recorder (General Scanning Inc., Bedford MA).

5 In the first test procedure, the rats were surgically prepared (open chest, but no occlusion) and were administered TNF, sphingomyelin, or sphingosine by slow i.v. infusion (0.1 mg/kg over 5 minutes). Each animal was observed continuously for 15 10 minutes, whereupon a second does was administered by slow i.v. infusion (0.3 mg/kg over 5 minutes) and each animal was again observed for 15 minutes.

In the second test procedure, the main coronary artery of rats undergoing 15 coronary occlusion was located and occluded close to its origin using a 5-0 suture passed underneath the vessel that could be tightened over a short section of PE tubing (PE 20) to initiate regional ischemia. Reperfusion was reinstated by removing the short segment of PE tubing.

20 Determination of infarct size. The heart was removed and sliced in five to six coronal sections, which were immersed in 1% triphenyltetrazolium chloride (TTC) for 10-15 minutes. The heart sections were removed, blotted dry and traced onto acetate sheets. The areas of infarction were clearly demarcated by a pale appearance in the ischemic zone, and a brick red color of non-infarcted myocardium. The areas of all sections were determined by planimetric methods and infarct area was expressed as a percentage of the left ventricle.

25

TNF Determination in Rat Serum. Blood samples were collected in syringes in the absence of any anticoagulant and immediately placed in Microtainer® serum separator tubes (Becton Dickinson) and centrifuged at 2000 g for 6 minutes. The serum was removed, frozen immediately, and stored at -20°C until the analysis could 30 be performed. The concentration of serum TNF collected at preselected time points was determined for individual rats by enzyme-linked immunosorbent assay (ELISA), utilizing the Factor-Test-X (Genzyme Inc, Cambridge, MA., Cat #80-3905-01)

- 8 -

according to the manufacturer's instructions. Briefly, 100 μ L of serum was diluted 1:2 in 0.1% bovine serum albumin/phosphate buffered saline and added in duplicate to a 96-well microtiter plate. A standard curve was generated by plotting the concentrations of rat TNF standards versus their absorbances. The manufacturer of 5 the assay and validation in our laboratory have indicated that this assay is able to detect both free TNF and TNF bound to etanercept (data not shown). The detection limit of this assay was 10 pg/mL. Additionally, the manufacturer has determined that this ELISA is highly specific for rat TNF. Concentrations that reached 10^6 pg/mL of 10 rat IFN- γ , GRO- β /MIP-2, GRO/KC, and interleukins IL-1 β , IL-2, and IL-4, as well as mouse LIF, SCF, GM-CSF, and interleukins IL-1 α , IL-3, IL-5, IL-6, IL-7, and IL-10, did not yield detectable cross reactivity.

Ventricular Myocyte Isolation. Ventricular myocytes were isolated using a modified Langendorff perfusion procedure outlined by Silver, et al., (13) Briefly, 15 cats of either sex, weighing 2-4 kg were anaesthetized with pentobarbital sodium (40 mg/kg I.P.). Under anesthesia, a sternotomy was performed, the heart rapidly excised, and then immersed in Ca^{++} -free Krebs-Henseleit buffer solution (KHB) at 4°C for aortic cannulation. KHB had the following composition (in mM): 130 NaCl, 4.8 KCl, 1.2 MgSO_4 , 1.2 NaH_2PO_4 , 25 NaHCO_3 , 12.5 dextrose. Solution pH was 7.35-7.40 20 when equilibrated with 95% O_2 /5% CO_2 gas mixture. The solution was actively aerated throughout the procedure. The cannulated heart was rinsed with KHB at 37°C for 2-4 minutes followed by perfusion for 12-15 minutes with KHB containing 0.7 mg/mL Type II collagenase (197 U/mg; Worthington; Freehold, NJ USA). 25 Digested ventricular tissue was then dissected from the atria, minced, and filtered through a 200 μ m pore nylon mesh. Filtrate was centrifuged at 50 x g for 1-2 minutes and the separated cell pellet was resuspended in fresh KHB. The latter process was performed three times. On the third iteration, the pellet was resuspended with KHB containing 2% bovine serum albumin and 100 μ M Ca^{++} . The resulting cell suspension was divided into two aliquots. One was diluted 1:1 with Tyrode's solution 30 (composition below), maintained at room temperature (19-25°C), and was used for cellular recordings within 12 hours of isolation. The second aliquot was utilized to

- 9 -

plate cells used for subsequent recordings and was dispensed into a 1:1 mix of DMEM/F-12 culture media (Bio Whittaker, Walkersville, MD, USA), supplemented with streptomycin sulfate (200 μ g/mL) and penicillin-G sodium salt (200 units/mL). Plated cells were maintained at room temperature in an incubator (pH=7.2). The 5 suspension media was changed every two days.

Myocyte Electrophysiological Recording. Patch-clamp current and voltage recordings were made with the ruptured patch whole-cell configuration at 36-37°C (14). For studies on L-type Ca^{2+} currents, cells were bathed with modified Tyrode's 10 containing (in mM): 157 TEA-Cl, 5 CaCl_2 , 0.5 MgCl_2 , and 10 HEPES. Electrode internal solution contained (in mM): 10 L-Glutamic Acid, 20 CsCl , 10 EGTA, 1 MgCl_2 , 1 CaCl_2 , 20 HEPES, and 5 ATP- Mg^{2+} ; pH adjusted with CsOH . In all of the studies, electrode resistance was measured to be 2-3.5 $\text{M}\Omega$. The reference zero potential was adjusted in the bath before forming seals. Recordings were performed 15 with an Axon Instruments 200B amplifier (Axon Instruments, Culver City, CA USA) interfacing a DigiData 1200 DA/AD acquisition system. Ionic currents were evoked by depolarizing voltage step (1 sec-long) from -30 to +60 mV, in 10-mV increments, from a holding potential of -40 mV delivered at the frequency of 1 Hz. Action potentials were elicited at a frequency of 1 Hz by injection of brief depolarizing 20 current pulses. Software used in data acquisition and analysis was pClamp v.6.04 and Origin v 5.0 (Microcal Software, Northampton, MA).

Results

Hemodynamic Parameters in Non-Occluded Rats. The following table shows 25 the effects of sphingosine, sphingomyelin, and TNF on the following hemodynamic parameters in open chest rats in the absence of myocardial ischemia: heart rate, mean blood pressure, left ventricular blood pressure (LVL) and its first derivative (+dP/dt).

- 10 -

Cardiovascular parameters measured in open chest rats in the absence of myocardial ischemia.

	<u>GROUPS</u>	<u>Heart Rate</u>	<u>Mean BP</u>	<u>LVPdev</u>	<u>+dP/dt</u>
5	Rat TNF-α				
	0.1 mg/kg iv (n=5)	-3±1	4±7	1±4	10±5
	+ 0.3 mg/kg iv	-3±2	4±6	-1±3	9±8
10	Sphingomyelin				
	0.1 mg/kg iv (n=4)	7±9	-3±17	3±11	1±13
	+ 0.3 mg/kg iv	8±10	2±2	4±12	6±15
15	Sphingosine				
	0.3 mg/kg iv (n=4)	-4±4	-24±12	-24± 8*	-33±12*
	+ 1.0 mg/kg iv	-18±1*	-17±19	-24±14	-32±18*

20 Data are expressed as mean ± sem. Data are percent change from pre-drug baseline 15 minutes after drug administration. * indicates p<0.05 vs other pretreatment groups over the entire observation period.

25 The results of this test procedure show that following infusion of sphingosine (0.1+0.3 mg/kg), overall myocardial function was significantly depressed: LVP was depressed by 24±8% and +dP/dt was reduced 33±12% from baseline. The dose of TNF that was administered exogenously to the rats in this test procedure resulted in serum concentrations two-fold higher than the C_{max} of TNF generated endogenously after myocardial ischemia. However, even very high serum concentrations of TNF 30 failed to produce acute cardiodepression in the absence of an inflammatory response, which is necessary for initiation of the sphingolipid cascade. In the absence of myocyte injury, one would not expect sphingomyelin administration to depress function since membrane sphingomyelinases would not have been stimulated by increased concentrations of TNF to degrade sphingomyelin to ceramide, the 35 metabolite previously shown to decrease contractility in isolated myocytes.

Effects of Sphingosine on Isolated Myocytes. To further evaluate the effects of sphingosine on cardiac function and cellular injury, isolated myocytes were isolated and the effects of sphingosine on calcium currents were measured as 5 described above. Previous studies have shown that sphingosine can effect the electrogenesis of the action potential by decreasing Ca^{+2} release from the sarcoplasmic reticulum [Yasui, et al. *Am J. Physiol.* 270: C645-C649 (1996); MacDonell, et al. *Am J. Physiol.* 275: H2291-H2299 (1998)]. The results obtained in the standard pharmacological test procedure described above showed that sphingosine shortened 10 the action potential duration (APD) of isolated feline ventricular myocytes in a concentration-dependent manner, with 0.25, 2.5 and 25 μM sphingosine reducing the duration at 95% of full repolarization (APD_{95}) by 16 \pm 2%, 28 \pm 2%, and 39 \pm 2% (n=4), respectively. The shortening of APD was mostly the result of a depression of the plateau phase. The Ca^{+2} current ($I_{\text{Ca-L}}$) was isolated by suppressing other K^{+} currents 15 by using Cs^{+} , a blocker of K^{+} currents, in both the external and in the pipette solution. The fast Na^{+} current (I_{Na}) was eliminated by holding the myocytes at -40 mV, a potential where (I_{Na}) is largely inactivated, and by substituting NaCl with TEA-Cl in the external solution. Exposure to sphingosine (2.5 and 25 μM) caused a significant 20 block of $I_{\text{Ca-L}}$ (17 \pm 7 and 75 \pm 4% block at 25 μM). The shortening of the cardiac action potential and reducing the inward Ca^{+2} current would be expected to correlate with the negative inotropic changes seen directly following systemic administration or, indirectly, following activation of TNFR1. Ultimately, sphingosine (25 μM) lead to 25 myocardial cell death assessed by its resulting morphology and lack of viability soon after exposure to sphingosine at the highest concentration. Treatment of myocytes with TNF (200-20,000 U/mL) did not alter action potential or $I_{\text{Ca+2-L}}$.

TNF Levels in Occluded Rats. As described above, rats were surgically prepared and the coronary artery was occluded. The following table shows the serum concentration of TNF in open chest rats undergoing myocardial ischemia.

- 12 -

<u>GROUPS</u>	<u>Vehicle</u>	<u>Etanercept</u>
5	-30 min	0±0
	0 min	6056±925
	30 min	2122±371
	60 min	740±153
	90 min	585±112
	120 min	338±44
	150 min	204±7

10 Data are expressed as mean ± sem in units of pg/ml.

* indicates p<0.05 vs the vehicle treatment group at the identical timepoint.

Baseline = -30 min,

End of Ischemia = 0 min, and Reperfusion = 30,60,90.....min.

15

In this test procedure, rats that had their chests surgically opened, but did not have any induced occlusion (sham-operated animals) had a stable TNF α concentration throughout the duration of the procedure, with a maximum concentration of 242±90 pg/mL. These data show that vascular occlusion produced vastly increased levels of TNF α , which peaked at the conclusion of the ischemic period. The results also showed that etanercept significantly reduced the massive TNF α spike in concentration in response to vascular occlusion at 0 minutes.

20
25 Effect of TNF α Antagonist Treatment on Mortality in Occluded Rats. The percent survival following myocardial ischemia/reperfusion was also evaluated in this test procedure. The results obtained are summarized in the table below.

- 13 -

Percent survival of open chest rats undergoing myocardial ischemia/reperfusion in the presence or absence of etanercept (3mg/kg iv).

	GROUPS	Vehicle	Etanercept
5	-30 min	100	100
	0 min	100	100
	30 min	83	100
	60 min	66	100
	90 min	50	89
10	120 min	33	89*
	150 min	17	88*

Data are expressed as percent survival.

* indicates p<0.05 vs the vehicle treatment group at the identical timepoint.

Baseline = -30 min,

End of Ischemia = 0 min, and Reperfusion = 30,60,90.....min.

In this standard pharmacological test procedure, etanercept (3 mg/kg i.v.) administered immediately before occlusion significantly reduced mortality resulting from the myocardial ischemia/reperfusion. During the latter stages of reperfusion (t=90 minutes) a difference began to emerge with regard to overall mortality. For example, 4 out of 9 rats were dead at t=90 minutes in the vehicle treated group compared to 1 out of 9 in the etanercept treated group, though the difference failed to reach statistical significance (p=0.08). The difference between the etanercept and vehicle-control groups achieved statistical significance at 120 and 150 min of reperfusion. Of the seven deaths observed in the vehicle-treated group, six were due to acute pump failure and progressive bradycardia, and one animal died of ventricular arrhythmias early after reperfusion. The two deaths in the etanercept treated group were both due to bradycardia and pump failure. Infarct size, expressed as a percentage of the left ventricle, was 24±3% for Etanercept and 26±2% for the vehicle-control group, showing that the difference of survival was not the result of unequal infarct size. These results demonstrate that treatment with a TNF α antagonist reduced the mortality resulting from myocardial ischemia/reperfusion, presumably by preventing the cascade generating sphingosine from sphingomyelin

- 14 -

which follows TNF α binding to TNFR1 in response to the ischemic/reperfusion injury.

Based on the results obtained in the standard pharmacological test procedures
5 described above, TNF α antagonists are useful in reducing mortality following
myocardial infarction. Based on the results obtained, TNF α antagonists are also
useful in treating or inhibiting cellular injury or cell death following an ischemic
event. More particularly, this invention provides a method of treating or inhibiting
cellular injury or cell death resulting from myocardial infarction, myocardial
10 ischemia, retinal ischemia, central retinal occlusion, peripheral arterial occlusion (i.e.,
an embolism), transient ischemic attacks (i.e., cerebral ischemic attacks), ischemic
stroke, ischemic arterial obstruction, injury resulting from frostbite, arterial
thrombosis and occlusion, and crush injury. This invention is also useful in treating
or inhibiting reperfusion injury. Treatment with a TNF α antagonist will also be
15 useful prior to or during procedures which involve ischemic events followed by
reperfusion, such as transplant surgery, when the donor organ undergoes a period of
ischemia, and is then reperfused by the recipients blood supply; angioplasty or
coronary stent placement; thrombolytic therapy; heart valve replacement; and bypass
surgery.

20

TNF α antagonists may be formulated neat or may be combined with one or
more pharmaceutically acceptable carriers for administration according to standard
method for the formulation of pharmaceutical agents. Routes of administration
include oral, parenteral (including, for example, intravenous, intramuscular injection,
25 subcutaneous injection), intranasal, intraperitoneal, rectal, vaginal, and transdermal.
The routes of administration vary with the nature of the TNF α antagonist and reason
for administration. For example, where the TNF α antagonist will rapidly degrade in
the gut, administration is preferably made parenterally. It is preferable to provide
etanercept intravenously for the treatment or inhibition of cellular injury or cell death
30 following an ischemic event, because of the acid labile nature of etanercept and the
necessity for rapid onset of action.

- 15 -

When the TNF α antagonist is to be provided orally, it can be provided in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from 5 about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solution or suspension containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 0.05 up to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.

10 Formulation for tablet or capsule administration may include solid carriers including starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired.

15 Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.

When the TNF α antagonist is to be administered parenterally or intraperitoneally, solutions or suspensions of these active compounds as a free base or 20 pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparation contain a preservative to prevent the growth of microorganisms.

25 The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the 30 contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures

- 16 -

thereof, and vegetable oils. Etanercept, for example is commercially available as a white, preservative free, lyophilized powder for parenteral administration after reconstitution with water.

5 It is anticipated that the dosage the TNF α antagonist will vary according to the nature of the TNF α antagonist, the reason for administration, and individual patient receiving therapy. For chronic therapy, it is generally recommended that treatment begin with the smallest effective dosage, with dosage adjustments being made through physician monitoring. For treatment with etanercept, projected intravenous
10 dosage would be between 0.05 - 25 mg/kg etanercept. It is contemplated that the TNF α antagonist may be administered in a single dose or over several doses in response to a particular ischemic event, or may be administered chronically to inhibit cellular damage or death in response to future ischemic events. For example, it is anticipated that a TNF α antagonist may be administered chronically to a patient
15 suffering from transient ischemic events, which often occur over long periods of time. Alternatively, it is also contemplated that the TNF α antagonist may be administered prophylactically in situations where it is anticipated that an ischemic event will occur (for example, prior to a transplant procedure or angioplasty procedure).

CLAIMS

1. A method of treating or inhibiting cellular injury or inhibiting cell death following an ischemic event in a mammal in need thereof, which comprises providing an effective amount of a TNF α antagonist to said mammal.
2. The method according to claim 1, wherein the cellular injury or death results from myocardial infarction, myocardial ischemia, retinal ischemia, central retinal occlusion, peripheral arterial occlusion, transient ischemic attacks, ischemic stroke, ischemic arterial obstruction, frostbite, arterial thrombosis and occlusion, or crush injury.
3. The method according to claim 1, wherein the TNF α antagonist is a TNF receptor/immunoglobulin fusion protein.
4. The method according to claim 3, wherein the TNF α antagonist comprises a fragment of TNFR and a portion or the entire constant region of a human immunoglobulin heavy chain.
5. The method according to claim 4, wherein the TNF α antagonist is etanercept.
6. The method according to claim 4, wherein the TNF α antagonist is p55TNFR:Fc.
7. A method of treating or inhibiting reperfusion injury in a mammal in need thereof, which comprises providing an effective amount of a TNF α antagonist to said mammal.
8. The method according to claim 7, wherein the injury results from transplant surgery, angioplasty, coronary stent placement, thrombolytic therapy, heart valve replacement, or bypass surgery.
9. The method according to claim 7, wherein the TNF α antagonist is a TNF receptor/immunoglobulin fusion protein.

- 18 -

10. The method according to claim 9, wherein the TNF α antagonist comprises a fragment of TNFR and a portion or the entire constant region of a human immunoglobulin heavy chain.
- 5 11. The method according to claim 10, wherein the TNF α antagonist is etanercept.
12. The method according to claim 10, wherein the TNF α antagonist is p55TNFR:Fc.
- 10 13. A method of reducing mortality following a myocardial infarction in a mammal in need thereof, which comprises providing an effective amount of a TNF α antagonist to said mammal.
14. The method according to claim 13, wherein the TNF α antagonist is a TNF receptor/immunoglobulin fusion protein.
- 15 15. The method according to claim 14, wherein the TNF α antagonist comprises a fragment of TNFR and a portion or the entire constant region of a human immunoglobulin heavy chain.
- 20 16. The method according to claim 15, wherein the TNF α antagonist is etanercept.
17. The method according to claim 15, wherein the TNF α antagonist is p55TNFR:Fc.
- 25 18. The use of a TNF α antagonist in the manufacture of a medicament for preventing, treating or inhibiting cellular injury or cell death due to an ischemic event.
19. The use of a TNF α antagonist in the manufacture of a medicament for preventing, treating or inhibiting reperfusion injury.
- 30 20. The use of a TNF α antagonist in the manufacture of a medicament for reducing mortality following a myocardial infarction.
- 35 21. A use as claimed in claim 18 wherein the cellular injury or death results from myocardial infarction, myocardial ischemia, retinal ischemia, central retinal

- 19 -

occlusion, peripheral arterial occlusion, transient ischemic attacks, ischemic stroke, ischemic arterial obstruction, frostbite, arterial thrombosis and occlusion, or crush injury.

5 22. A use as claimed in any one of claims 18 to 21 wherein the TNF α antagonist is a TNF receptor/immunoglobulin fusion protein.

10 23. A use as claimed in any one of claims 18 to 21 wherein the TNF α antagonist comprises a fragment of TNFR and a portion or the entire constant region of a human immunoglobulin heavy chain.

24. A use as claimed in any one of claims 18 to 21 wherein the TNF α antagonist is etanercept.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/04048

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K38/17 A61P9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 30088 A (KENNEDY INST OF RHEUMATOLOGY) 21 August 1997 (1997-08-21) * see claims, pages 5-6 and 24-27 *	1,2,7, 13,18-21 1-24
X,P	--- WO 00 62790 A (FINCK BARBARA K ;IMMUNEX CORP (US)) 26 October 2000 (2000-10-26) * see pages 5-6 and 10-11 *	1-24
X	--- WO 99 64419 A (MIGNANI SERGE ;NEMECEK CONCEPTION (FR); RHONE POULENC RORER SA (FR) 16 December 1999 (1999-12-16) * see abstract and pages 11-13 *	1,2,7,8, 13,18-21
	---	-/--

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

30 May 2001

Date of mailing of the international search report

22/06/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Merckling, V

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/04048

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 06042 A (SMITHKLINE BEECHAM CORP ;LEE DENNIS (US); LONG SCOTT A (US)) 11 February 1999 (1999-02-11) * see page 5 lines 26-29, page 8 lines 25-34, page 24 and table 1 * ---	1,2,7,8, 13,18-21
X	WO 99 34084 A (DUTCH TRADING DUTRA B V ;LANGE JOHANNES ANDREAS DE (NL)) 8 July 1999 (1999-07-08) * see abstract, pages 6-7 and page 12 * ---	1,2,7,8, 13,18-21
Y	US 5 610 279 A (BROCKHAUS MANFRED ET AL) 11 March 1997 (1997-03-11) cited in the application * see abstract, col.9 first paragraph and example 11 * ---	1-24
Y	LEE J C ET AL: "LOW-MOLECULAR-WEIGHT TNF BIOSYNTHESIS INHIBITORS: STRATEGIES AND PROSPECTIVES" CIRCULATORY SHOCK, XX, XX, vol. 44, no. 3, 1 November 1994 (1994-11-01), pages 97-103, XP000560042 ISSN: 0092-6213 * see the whole document * -----	1,2,7,8, 13,18-21

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claims 1-2, 7-8, 13 and 18-21 may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of these claims is impossible. Consequently, the search has been restricted to: the TNF-alpha antagonists as defined in claims 3-6 and to the general concept of TNF-alpha antagonists/inhibitors. However, it was not possible to cite all documents disclosing the use of TNF-alpha antagonizing-compounds for treating the same diseases as in the application. Claims 1-2, 7-8, 13 and 18-21 have been searched partially.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/04048

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9730088	A 21-08-1997	CA 2246297	A	21-08-1997	
		EP 0882067	A	09-12-1998	
		JP 2000504716	T	18-04-2000	
WO 0062790	A 26-10-2000	AU 4363200	A	02-11-2000	
WO 9964419	A 16-12-1999	FR 2779724	A	17-12-1999	
		AU 4045899	A	30-12-1999	
		EP 1086100	A	28-03-2001	
WO 9906042	A 11-02-1999	AU 8762898	A	22-02-1999	
		EP 0988035	A	29-03-2000	
		US 6214858	B	10-04-2001	
		ZA 9806761	A	01-02-1999	
WO 9934084	A 08-07-1999	NL 1007890	C	12-07-1999	
		AU 1787899	A	19-07-1999	
		EP 1042579	A	11-10-2000	
US 5610279	A 11-03-1997	US 5808029	A	15-09-1998	
		AT 194384	T	15-07-2000	
		DE 59010908	D	10-08-2000	
		DK 417563	T	06-11-2000	
		EP 0417563	A	20-03-1991	
		EP 0939121	A	01-09-1999	
		JP 2728968	B	18-03-1998	
		JP 4164099	A	09-06-1992	
		JP 10114795	A	06-05-1998	
		JP 10095800	A	14-04-1998	